PARAGON CARE LIMITED (PGC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PGC

PGC - PARAGON CARE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.04
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.13

25 Jun
2026

-0.005

OPEN

$0.13

-3.70%

HIGH

$0.14

312,018

LOW

$0.13

TARGET
$0.17

-0.08 change from previous day

 30.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PGC: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 1.0 1.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 9.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 18/09 - ex-div 0.6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx3,680.5 M
Book Value Per Share xxxxxxxxxxxxxxx17.9
Net Operating Cash Flow xxxxxxxxxxxxxxx29.1 M
Net Profit Margin xxxxxxxxxxxxxxx-0.44 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-5.12 %
Return on Invested Capital xxxxxxxxxxxxxxx-3.57 %
Return on Assets xxxxxxxxxxxxxxx-1.19 %
Return on Equity xxxxxxxxxxxxxxx-5.12 %
Return on Total Capital xxxxxxxxxxxxxxx2.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx237 M
Long Term Debt xxxxxxxxxxxxxxx152 M
Total Debt xxxxxxxxxxxxxxx389 M
Goodwill - Gross xxxxxxxxxxxxxxx333 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx24 M
Price To Book Value xxxxxxxxxxxxxxx0.76

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx33.2 M
Capex % of Sales xxxxxxxxxxxxxxx0.90 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,523 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx141 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/06/2026

3

Downgrade to Hold from Buy

$0.17

30.77%

Paragon Care now expects FY26 revenue of $3.7bn and EBITDA in the range of $95-$100m, including the 3-month contribution from Haju Medical.

Bell Potter, in assessing the slight downgrade from prior guidance of $97-$107m, is not surprised given the increased costs of logistics and supplier price increases as a result of the conflict in the Middle East.

Administrators of Infinity Group have advised of a preliminary settlement estimate to Paragon Care in the range of $11.7-$15.8m.

The company had previously provided for the entire $49m. The estimated settlement follows submissions of offers for various pharmacies within the group, most of which continue to trade.

The broker notes the second half was difficult for the company in spite of two accretive acquisitions amid inflationary pressures in the core Australian business.

Rating is downgraded to Hold from Buy and the target is lowered to $0.17 from $0.30.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.30 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

PGC STOCK CHART

FNArena News on PGC

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia